Compare Stocks: PRGO, LQDA, LNTH, and BLTE

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BLTE Belite Bio	$161.06 -0.5%	$154.99	$62.18 ▼ $200.00	$6.46B	-1.22	178,836 shs	111,217 shs
LNTH Lantheus	$99.97 -0.3%	$104.08	$49.67 ▼ $111.86	$6.53B	-0.03	2.17 million shs	1.08 million shs
LQDA Liquidia	$68.62 -3.4%	$79.29	$21.15 ▼ $93.61	$6.14B	0.58	1.62 million shs	1.70 million shs
PRGO Perrigo	$14.22 +3.8%	$11.07	$9.23 ▼ $24.60	$1.98B	0.51	2.95 million shs	2.60 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BLTE Belite Bio	0.00%	-1.07%	+3.06%	+17.31%	+153.96%
LNTH Lantheus	0.00%	-0.97%	-3.62%	-2.94%	+78.07%
LQDA Liquidia	0.00%	-7.82%	-22.92%	+12.53%	+150.90%
PRGO Perrigo	0.00%	+9.16%	+40.74%	+26.88%	-39.96%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BLTE Belite Bio	$161.06 -0.5%	$154.99	$62.18 ▼ $200.00	$6.46B	-1.22	178,836 shs	111,217 shs
LNTH Lantheus	$99.97 -0.3%	$104.08	$49.67 ▼ $111.86	$6.53B	-0.03	2.17 million shs	1.08 million shs
LQDA Liquidia	$68.62 -3.4%	$79.29	$21.15 ▼ $93.61	$6.14B	0.58	1.62 million shs	1.70 million shs
PRGO Perrigo	$14.22 +3.8%	$11.07	$9.23 ▼ $24.60	$1.98B	0.51	2.95 million shs	2.60 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BLTE Belite Bio	0.00%	-1.07%	+3.06%	+17.31%	+153.96%
LNTH Lantheus	0.00%	-0.97%	-3.62%	-2.94%	+78.07%
LQDA Liquidia	0.00%	-7.82%	-22.92%	+12.53%	+150.90%
PRGO Perrigo	0.00%	+9.16%	+40.74%	+26.88%	-39.96%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BLTE Belite Bio	2.63	Moderate Buy	$205.80	27.78% Upside
LNTH Lantheus	2.29	Hold	$108.11	8.14% Upside
LQDA Liquidia	2.45	Hold	$98.08	42.94% Upside
PRGO Perrigo	2.00	Hold	$19.33	35.96% Upside

Current Analyst Ratings Breakdown

Latest PRGO, LQDA, LNTH, and BLTE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2026	BLTE Belite Bio	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/17/2026	LNTH Lantheus	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold
8/14/2026	BLTE Belite Bio	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$201.00 ➝ $206.00
8/14/2026	BLTE Belite Bio	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/14/2026	BLTE Belite Bio	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$220.00
8/13/2026	LNTH Lantheus	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C+) ➝ Hold (C)
8/13/2026	LQDA Liquidia	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Strong-Buy	$106.00
8/13/2026	LQDA Liquidia	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$62.00 ➝ $108.00
8/13/2026	LQDA Liquidia	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/13/2026	LQDA Liquidia	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$79.00 ➝ $92.00
8/12/2026	BLTE Belite Bio	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$266.00 ➝ $270.00

(Data available from 8/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BLTE Belite Bio	N/A	N/A	N/A	N/A	$19.38 per share	N/A
LNTH Lantheus	$1.56B	4.19	$6.38 per share	15.66	$20.10 per share	4.97
LQDA Liquidia	$158.32M	38.80	N/A	N/A	$2.18 per share	31.48
PRGO Perrigo	$4.25B	0.46	$5.29 per share	2.69	$18.13 per share	0.78

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BLTE Belite Bio	-$77.61M	-$2.73	N/A	173.18	N/A	N/A	-11.84%	-11.62%	11/9/2026 (Estimated)
LNTH Lantheus	$233.56M	$4.14	24.15	18.48	N/A	17.69%	28.10%	14.35%	11/5/2026 (Estimated)
LQDA Liquidia	-$68.92M	$1.37	50.09	15.67	N/A	30.74%	149.65%	36.30%	11/2/2026 (Estimated)
PRGO Perrigo	-$1.43B	-$12.51	N/A	5.90	1.62	-41.85%	11.25%	4.08%	11/4/2026 (Estimated)

Latest PRGO, LQDA, LNTH, and BLTE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	BLTE Belite Bio	-$0.73	-$0.54	+$0.19	-$0.70	N/A	N/A
8/12/2026	Q2 2026	LQDA Liquidia	$0.7580	$0.74	-$0.0180	$0.74	$168.48 million	$171.68 million
8/6/2026	Q2 2026	LNTH Lantheus	$1.30	$1.55	+$0.25	$1.11	$363.23 million	$388.18 million
8/5/2026	Q2 2026	PRGO Perrigo	$0.3880	$0.50	+$0.1120	$0.53	$1.02 billion	$1.02 billion
6/30/2026	Q2 2026	BLTE Belite Bio	N/A	-$0.54	N/A	-$0.70	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BLTE Belite Bio	N/A	N/A	N/A	N/A	N/A
LNTH Lantheus	N/A	N/A	N/A	N/A	N/A
LQDA Liquidia	N/A	N/A	N/A	N/A	N/A
PRGO Perrigo	$1.16	8.16%	+5.21%	N/A	23 Years

Latest PRGO, LQDA, LNTH, and BLTE Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/30/2026	PRGO Perrigo	quarterly	$0.29	11.19%	8/28/2026	8/28/2026	9/15/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BLTE Belite Bio	N/A	33.56	33.56
LNTH Lantheus	0.43	3.06	2.89
LQDA Liquidia	0.63	2.31	2.12
PRGO Perrigo	1.31	2.32	1.32

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BLTE Belite Bio	0.53%
LNTH Lantheus	99.06%
LQDA Liquidia	64.54%
PRGO Perrigo	95.91%

Insider Ownership

Company	Insider Ownership
BLTE Belite Bio	13.29%
LNTH Lantheus	1.70%
LQDA Liquidia	25.60%
PRGO Perrigo	0.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BLTE Belite Bio	10	40.08 million	34.76 million	Not Optionable
LNTH Lantheus	1,193	65.27 million	64.16 million	Optionable
LQDA Liquidia	50	89.51 million	66.60 million	Optionable
PRGO Perrigo	8,100	138.77 million	138.21 million	Optionable

PRGO, LQDA, LNTH, and BLTE Headlines

Recent News About These Companies

This Under-the-Radar Healthcare Stock Yields Nearly 8.5%. Here's Whether That Income Is Too Good to Be True.

August 22 at 5:51 PM | fool.com

Bank of America Corp DE Acquires 318,248 Shares of Perrigo Company plc $PRGO

August 21 at 3:12 AM | marketbeat.com

Perrigo Co. PLC stock underperforms Tuesday when compared to competitors despite daily gains

August 19, 2026 | marketwatch.com

Diamond Hill Capital Management LLC Investment Advisor Purchases New Stake in Perrigo Company plc $PRGO

August 18, 2026 | marketbeat.com

Perrigo Earnings Call Balances Pressure and Progress

August 16, 2026 | tipranks.com

Perrigo: The Rebound Is Just Getting Started

August 13, 2026 | seekingalpha.com

Perrigo (PRGO) Q2 2026 Earnings Call Transcript

August 12, 2026 | finance.yahoo.com

Perrigo (NYSE:PRGO) Stock Price Down 4.4% - Should You Sell?

August 12, 2026 | marketbeat.com

Perrigo Co. PLC stock outperforms competitors on strong trading day

August 11, 2026 | marketwatch.com

Sei Investments Co. Sells 121,359 Shares of Perrigo Company plc $PRGO

August 11, 2026 | marketbeat.com

PRGO vs. NEOG: Which Stock Is the Better Value Option?

August 10, 2026 | zacks.com

Are Investors Undervaluing Perrigo (PRGO) Right Now?

August 10, 2026 | zacks.com

Perrigo Q2 Earnings Call Highlights

August 8, 2026 | marketbeat.com

Perrigo (NYSE:PRGO) Upgraded by Wall Street Zen to "Buy" Rating

August 8, 2026 | marketbeat.com

Perrigo Company plc Q2 2026 Earnings Call Summary

August 7, 2026 | finance.yahoo.com

Quantinno Capital Management LP Sells 168,471 Shares of Perrigo Company plc $PRGO

August 7, 2026 | marketbeat.com

Perrigo Stock Rises 23% as Q2 Earnings & Sales Beat Estimates

August 6, 2026 | zacks.com

Perrigo: Q2 Earnings Snapshot

August 5, 2026 | wtop.comW

Top Biotech Gainers: ATTO Debuts, AMWL Cuts Loss, PRGO Returns To The Black, URGN Hits New High

August 5, 2026 | rttnews.com

Perrigo (NYSE:PRGO) Posts Quarterly Earnings Results, Beats Expectations By $0.16 EPS

August 5, 2026 | marketbeat.com

Perrigo Company plc 2026 Q2 - Results - Earnings Call Presentation

August 5, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRGO, LQDA, LNTH, and BLTE Company Descriptions

Belite Bio NASDAQ:BLTE

$161.06 -0.88 (-0.54%)

As of 08/21/2026 04:00 PM Eastern

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.

Lantheus NASDAQ:LNTH

$99.97 -0.27 (-0.27%)

As of 08/21/2026 04:00 PM Eastern

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Liquidia NASDAQ:LQDA

$68.62 -2.43 (-3.42%)

As of 08/21/2026 04:00 PM Eastern

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

Perrigo NYSE:PRGO

$14.22 +0.52 (+3.80%)

As of 08/21/2026 03:58 PM Eastern

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. It also offers healthy lifestyle products, such as smoking cessation, well-being, and weight management products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; rare diseases business; and other miscellaneous self-care products. The company sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, Compeed Stops, XLS, Arterin, Davitamon, Apiserum, Abtei, and Nicorette brands. It also offers contract manufacturing services. The company sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PRGO, LQDA, LNTH, and BLTE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PRGO, LQDA, LNTH, and BLTE Earnings

Compare Dividends

Latest PRGO, LQDA, LNTH, and BLTE Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PRGO, LQDA, LNTH, and BLTE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRGO, LQDA, LNTH, and BLTE Company Descriptions

Belite Bio NASDAQ:BLTE

Lantheus NASDAQ:LNTH

Liquidia NASDAQ:LQDA

Perrigo NYSE:PRGO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PRGO, LQDA, LNTH, and BLTE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PRGO, LQDA, LNTH, and BLTE Earnings

Compare Dividends

Latest PRGO, LQDA, LNTH, and BLTE Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PRGO, LQDA, LNTH, and BLTE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRGO, LQDA, LNTH, and BLTE Company Descriptions

Belite Bio NASDAQ:BLTE

Lantheus NASDAQ:LNTH

Liquidia NASDAQ:LQDA

Perrigo NYSE:PRGO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools